Major shareholder announcement: Re-delivery of shares
Regulatory Release 25/2021
June 01, 2021
Better Collective A/S (Danish company registration number 27652913) (the ”Company”) hereby announces that it has received the following notifications according to the Danish Capital Markets Act section 38 regarding certain existing direct and indirect major shareholders’ holding of shares in the Company. The information contained in this release is based on a share capital of the Company amounting to 54,282,929 shares, each with a nominal value of EUR 0.01.
Notice is hereby given that Chr. Dam Holding ApS and J. Søgaard Holding ApS, the individual holding companies of Co-founder and COO, Christian Kirk Rasmussen, and Co-founder and CEO, Jesper Søgaard, today has increased their respective shareholdings in the Company with 3,440,367 shares, each, due to a redelivery of lent shares from Nordea Advisory & ECM, part of Nordea Danmark, Filial af Nordea Bank Abp, Finland, as part of the lending arrangements related to the directed share issue. Reference is made to regulatory release no. 19 “Major shareholder announcement: Share lending arrangements” on May 27, 2021.
Following the redelivery of lent shares, Chr. Dam Holding ApS and J. Søgaard Holding ApS, each hold 10,671,179 shares in the Company corresponding to approximately 19.66% per cent each of the total outstanding shares in the Company. As a consequence of the above arrangement, the direct and indirect ownership of Jesper Søgaard and Christian Kirk Rasmussen each amounts to 19.93% per cent (including warrants).
Contacts
Head of investor relations: Christina Bastius Thomsen, tel. +45 2363 8844
E-mail: Investor@bettercollective.com
This information is information which Better Collective A/S is obliged to make public pursuant to the Danish Capital Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 3:30 p.m. CET on June 01, 2021.
About Better Collective
Better Collective is a global sports betting media group providing platforms that empower and enhance the betting experience for sports fans and iGamers. Aiming to make betting and gambling more entertaining, transparent and fair, Better Collective offers a range of editorial content, bookmaker information, data insights, betting tips, iGaming communities and educational tools. Its portfolio of websites include bettingexpert.com, VegasInsider.com, HLTV.org and Action Network. Better Collective is headquartered in Copenhagen, Denmark, and listed on Nasdaq Stockholm (BETCO). More information at bettercollective.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares23.4.2024 22:17:37 CEST | Press release
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running mana
Interoil's Annual Statement of Reserves 2023 released23.4.2024 21:35:25 CEST | Press release
Oslo, 23 April 2024 Interoil Exploration and Production ASA today released the Annual Statement of Reserves for 2023. Please find the document attached. The report is also available on the company website. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act and is prepared in accordance with Oslo Stock Exchange's Listing and disclosure requirements for oil and natural gas companies. + + + Please direct any question to ir@interoil.no Interoil Exploration and Production ASA is a Norwegian based exploration and production company - listed on the Oslo Stock Exchange - with focus on Latin America. The Company is operator and license holder of several production and exploration assets in Colombia and Argentina. Interoil currently employs approximately 50 people and is headquartered in Oslo. Attachment Interoil reserves statement 2023
Nokia Corporation: Repurchase of own shares on 23.04.202423.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 23 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 23.04.2024 Espoo, Finland – On 23 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6153.40CEUX--BATE--AQEU--TQEX--Total385,6153.40 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro
Grant of warrants23.4.2024 19:20:21 CEST | Press release
23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o